Entrada Therapeutics Valuation
| TRDA Stock | USD 19.37 0.33 1.73% |
At this time, the firm appears to be undervalued. Entrada Therapeutics shows a prevailing Real Value of $21.48 per share. The current price of the firm is $19.37. Our model computes the value of Entrada Therapeutics from reviewing the firm fundamentals such as Profit Margin of 0.26 %, current valuation of 324.45 M, and Shares Outstanding of 37.42 M as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Entrada Therapeutics' valuation include:
Price Book 1.6865 | Enterprise Value 324.4 M | Enterprise Value Ebitda 5.2928 | Price Sales 3.3103 | Forward PE 3.3 K |
Undervalued
Today
Please note that Entrada Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Entrada Therapeutics is based on 3 months time horizon. Increasing Entrada Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Entrada Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Entrada Stock. However, Entrada Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 19.37 | Real 21.48 | Target 25.0 | Hype 19.21 |
The real value of Entrada Stock, also known as its intrinsic value, is the underlying worth of Entrada Therapeutics Company, which is reflected in its stock price. It is based on Entrada Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Entrada Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Entrada Therapeutics helps investors to forecast how Entrada stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Entrada Therapeutics more accurately as focusing exclusively on Entrada Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Entrada Therapeutics' intrinsic value based on its ongoing forecasts of Entrada Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Entrada Therapeutics' closest peers. If more than one evaluation category is relevant for Entrada Therapeutics we suggest using both methods to arrive at a better estimate.
Entrada Therapeutics Cash |
|
Entrada Valuation Trend
Comparing Entrada Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of Entrada Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Entrada Therapeutics Total Value Analysis
Entrada Therapeutics is at this time forecasted to have valuation of 324.45 M with market capitalization of 712.48 M, debt of 68.23 M, and cash on hands of 244.25 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Entrada Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
324.45 M | 712.48 M | 68.23 M | 244.25 M |
Entrada Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Entrada Therapeutics has an asset utilization ratio of 27.5 percent. This suggests that the Company is making $0.27 for each dollar of assets. An increasing asset utilization means that Entrada Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Entrada Therapeutics Ownership Allocation
Entrada Therapeutics holds a total of 37.42 Million outstanding shares. The majority of Entrada Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Entrada Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Entrada Therapeutics. Please pay attention to any change in the institutional holdings of Entrada Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Entrada Therapeutics Profitability Analysis
The company reported the previous year's revenue of 129.01 M. Net Loss for the year was (6.68 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Entrada Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Entrada Therapeutics and how it compares across the competition.
About Entrada Therapeutics Valuation
The stock valuation mechanism determines Entrada Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Entrada Therapeutics. We calculate exposure to Entrada Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Entrada Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 29.1 M | 30.6 M | |
| Pretax Profit Margin | 0.08 | 0.07 | |
| Operating Profit Margin | (0.02) | (0.02) | |
| Net Loss | (0.05) | (0.05) | |
| Gross Profit Margin | 0.20 | 0.18 |
Entrada Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 33.1 M | |
| Forward Price Earnings | 3333.3333 |
Entrada Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Entrada Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Entrada we look at many different elements of the entity such as Entrada's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Entrada Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Entrada Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Entrada Therapeutics' worth.Complementary Tools for Entrada Stock analysis
When running Entrada Therapeutics' price analysis, check to measure Entrada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entrada Therapeutics is operating at the current time. Most of Entrada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Entrada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entrada Therapeutics' price. Additionally, you may evaluate how the addition of Entrada Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |